Phosphate for Rickets

This trial aims to explore how phosphate treatments affect kidney, blood vessel, and heart health in individuals with specific genetic conditions: X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Participants will receive phosphate for 30 days to assess its impact on these conditions. The trial seeks individuals with XLH or HHRH who are willing to share past medical records and attend study visits. As an Early Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants a chance to contribute to groundbreaking medical insights.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team to understand any specific requirements.

Past studies have shown that using phosphate to treat X-linked hypophosphatemia (XLH) is generally safe. Researchers reported no serious side effects related to the treatment, indicating no major negative effects. Some patients experienced changes in calcium levels, but these were not serious, suggesting that people with XLH can tolerate the treatment well.

For hereditary hypophosphatemic rickets with hypercalciuria (HHRH), phosphate is a common treatment. Although specific studies on side effects are lacking, using phosphate for this condition is generally considered safe.

Researchers are excited about the phosphate treatment because it has the potential to address phosphate metabolism issues in conditions like X-linked hypophosphatemia and hereditary hypophosphatemic rickets (HHRH) more directly than current options. Most treatments for these conditions focus on managing symptoms or supplementing phosphate indirectly. However, this treatment aims to directly adjust phosphate levels and metabolism, potentially leading to more effective management and healthier aging. By focusing on the underlying metabolic issues, this approach could offer a more targeted and efficient solution compared to the standard care options available today.

This trial will evaluate phosphate treatment for patients with X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Research has shown that phosphate treatment strengthens bones, supports growth, and lessens pain in people with XLH. For those with HHRH, phosphate supplements have also proven beneficial. Small doses of oral phosphorus can balance phosphorus levels and improve bone health. Overall, these findings suggest that phosphate treatment can help manage symptoms in both XLH and HHRH.¹³⁴⁵⁶